These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38814433)

  • 41. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
    Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Carter K; Stakias V; Lippe R; Drogaris L; Soliman AM; Chen MM; Padilla B; Kivitz A
    Rheumatol Ther; 2024 Jun; 11(3):633-648. PubMed ID: 38498139
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
    Leonardi C; Maari C; Philipp S; Goldblum O; Zhang L; Burkhardt N; Ball S; Mallbris L; Gonzalez P; Fernández-Peñas P; Puig L
    J Am Acad Dermatol; 2018 Nov; 79(5):824-830.e2. PubMed ID: 29803904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis.
    Orbai AM; Gladman DD; Goto H; Birt JA; Gellett AM; Lin CY; Kvien TK
    Clin Exp Rheumatol; 2021; 39(2):329-336. PubMed ID: 32573426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A review of ixekizumab in the treatment of psoriatic arthritis.
    O'Rielly DD; Rahman P
    Expert Rev Clin Immunol; 2018 Dec; 14(12):993-1002. PubMed ID: 30360663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.
    Kavanaugh A; Marzo-Ortega H; Vender R; Wei CC; Birt J; Adams DH; Benichou O; Lin CY; Nash P
    Clin Exp Rheumatol; 2019; 37(4):566-574. PubMed ID: 30557128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A
    Puig L; Zhu B; Burge R; Shrom D; Dong Y; Shen W; Mallbris L; Reich K
    J Clin Aesthet Dermatol; 2020 Oct; 13(10):18-22. PubMed ID: 33584952
    [No Abstract]   [Full Text] [Related]  

  • 48. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain.
    Schweikert B; Malmberg C; Núñez M; Dilla T; Sapin C; Hartz S
    BMJ Open; 2020 Aug; 10(8):e032552. PubMed ID: 32792421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
    Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Carter K; Lippe R; Photowala H; Drogaris L; Soliman AM; Chen M; Padilla B; Behrens F
    Rheumatol Ther; 2024 Jun; 11(3):617-632. PubMed ID: 38498141
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
    Nash P; Kirkham B; Okada M; Rahman P; Combe B; Burmester GR; Adams DH; Kerr L; Lee C; Shuler CL; Genovese M;
    Lancet; 2017 Jun; 389(10086):2317-2327. PubMed ID: 28551073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early Onset of Clinical Improvement with Ixekizumab in a Randomized, Open-label Study of Patients with Moderate-to-severe Plaque Psoriasis.
    Khattri S; Goldblum O; Solotkin K; Amir Y; Min MS; Ridenour T; Yang FE; Lebwohl M
    J Clin Aesthet Dermatol; 2018 May; 11(5):33-37. PubMed ID: 29785237
    [No Abstract]   [Full Text] [Related]  

  • 52. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
    Combe B; Rahman P; Kameda H; Cañete JD; Gallo G; Agada N; Xu W; Genovese MC
    Arthritis Res Ther; 2020 Jan; 22(1):14. PubMed ID: 31964419
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
    Schett G; Chen W; Gao S; Chakravarty SD; Shawi M; Lavie F; Zimmermann M; Sharaf M; Coates LC; Siebert S
    Arthritis Res Ther; 2023 Aug; 25(1):150. PubMed ID: 37587493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.
    Blauvelt A; Muram TM; See K; Mallinckrodt CH; Crowley JJ; van de Kerkhof P
    J Dermatolog Treat; 2018 May; 29(3):220-229. PubMed ID: 28792259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
    Lebwohl MG; Gordon KB; Gallo G; Zhang L; Paul C
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):301-309. PubMed ID: 31479549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
    Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).
    Papp KA; Gerdes S; Leonardi CL; Elmaraghy H; See K; McKean-Matthews M; Konicek BW; Crane HM; Eastman W
    J Drugs Dermatol; 2021 Aug; 20(8):880-887. PubMed ID: 34397207
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
    Mease PJ; Fleischmann R; Deodhar AA; Wollenhaupt J; Khraishi M; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; van der Heijde D
    Ann Rheum Dis; 2014 Jan; 73(1):48-55. PubMed ID: 23942868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.